Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtype

British Journal of Pharmacology

Volumn 110, Issue 2, 1993, Pages 761-771

  Criscione, Leoluca ^a   de Gasparo, Marc ^a   Bühlmayer, Peter ^a   Whitebread, Steven ^a   Ramjoué, Hans‐peter R ^a   Wood, Jeanette ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Aldosterone; AT1 receptor; human myometrium; hypertension; losartan; marmoset; pithed rat; rabbit aorta; renal hypertensive rats; telemetry; valsartan

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR; LOSARTAN; RECEPTOR SUBTYPE; VALSARTAN;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; COW; DOSE RESPONSE; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MARMOSET; MYOMETRIUM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RAT;

ANGIOTENSIN I; ANIMAL; BIPHENYL COMPOUNDS; CATTLE; FEMALE; HUMAN; IMIDAZOLES; IN VITRO; LOSARTAN; MALE; RABBITS; RATS; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VALINE;

EID: 0027172062     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1993.tb13877.x     Document Type: Article

References (54)

1. Cardiac haemodynamic effects of the non‐peptide, angiotensin II‐receptor antagonist, DuP 753, in conscious Long Evans and Brattleboro rats
2. 2 subtype
3. 2 receptors do not interact with guanine nucleotide binding properties
4. 2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase
5. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein‐dye binding
6. Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives
7. Nomenclature for angiotensin receptors: a report of the nomenclature committee of the Council for High Blood Pressure Research
8. Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hemodynamic and biochemical consequences
9. Nonpeptide angiotensin II receptor antagonists: n‐((benzyloxy)benzyl) imidazoles and related compounds as potent antihypertensives
10. In vitro pharmacology of L‐158,809, a new highly potent and selective angiotensin II receptor antagonist
11. Identification of angiotensin II receptor subtypes
12. DuP 532. A second generation of nonpeptide angiotensin II receptor antagonists
13. In vitro pharmacology of DuP 753
14. Angiotensin II‐1 receptors mediate both vasoconstriction and hypertrophic responses in rat aortic smooth‐muscle cells
15. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II
16. Effects of enalapril on mortality in severe congestive heart failure
17. 1 angiotensin II receptor subtype
18. Binding characteristics and vascular effects of various angiotensin II antagonists
19. Pharmacology of angiotensin II‐receptor subtypes
20. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose‐response curve
21. 2) binding sites in R3T3 cells
22. The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives
23. A method of stimulating the complete sympathetic outflow from the spinal cord to the blood vessels in the pithed rat
24. Angiotensin II receptor heterogeneity
25. The renin‐angiotensin system: inhibitors and antagonists
26. Regulation of renin release and intrarenal formation of angiotensin: studies in the isolated rat kidney
27. Drugs and drug responses in isolated tissues
28. Controlled trial of Captopril in chronic heart failure: a rest and exercise hemodynamic study
29. Potent, orally active imidazo[4,5‐b]pyridine‐based angiotensin II receptor antagonists
30. LIGAND: a versatile computerized approach for the characterisation of ligand binding systems
31. Angiotensin converting enzyme inhibitors: an overview
32. Design of specific inhibitors of angiotensin converting enzyme: a new class of orally active antihypertensive agents
33. Role of the pressor action of angiotensin II in experimental hypertension
34. Historical development of saralasin
35. 1 receptor antagonists
36. Measurement of blood pressure and heart rate by telemetry in conscious unrestrained marmosets
37. Pharmacology of nonpeptide angiotensin II receptor antagonists
38. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices
39. Nonpeptide angiotensin II receptor antagonists: a novel class of antihypertensive agents
40. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists
41. Angiotensin II receptor antagonists: from discovery to antihypertensive drugs
42. Nonpeptide angiotensin II receptor antagonists
43. 1‐(Carboxybenzyl)‐imidazole‐5‐acrylic acids: potent and selective angiotensin II receptor antagonists
44. Preliminary biochemical characterization of two angiotensin II receptor subtypes
45. 2 receptors
46. Characterization of distinct angiotensin II binding sites in rat adrenal gland and bovine cerebellum using selective nonpeptide antagonists
47. Nonpeptide angiotensin II receptor antagonists IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent
48. Nonpeptide angiotensin II receptor antagonists studies with EXP 9270 and DuP 753
49. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP 3174: an active metabolite of DuP 753, an orally active antihypertensive agent
50. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists. X
51. 1 receptor antagonist
52. In vivo pharmacology of DuP 753
53. CGP 38 560 an orally active, low‐molecular‐weight renin inhibitor with high potency and specificity